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Abstract. 
 
Caveolin-1 is an integral membrane protein 
of caveolae that is thought to play an important role in 
both the trafﬁc of cholesterol to caveolae and modulat-
ing the activity of multiple signaling molecules at this 
site. The molecule is synthesized in the endoplasmic 
reticulum, transported to the cell surface, and under-
goes a poorly understood recycling itinerary. We have 
used mutagenesis to determine the parts of the mole-
cule that control trafﬁc of caveolin-1 from its site of 
synthesis to the cell surface. We identiﬁed four regions 
of the molecule that appear to inﬂuence caveolin-1 traf-
ﬁc. A region between amino acids 66 and 70, which is in 
the most conserved region of the molecule, is necessary 
for exit from the endoplasmic reticulum. The region be-
tween amino acids 71 and 80 controls incorporation of 
caveolin-1 oligomers into detergent-resistant regions of 
the Golgi apparatus. Amino acids 91–100 and 134–154 
both control oligomerization and exit from the Golgi 
apparatus. Removal of other portions of the molecule 
has no effect on targeting of newly synthesized caveo-
lin-1 to caveolae. The results suggest that movement of 
caveolin-1 among various endomembrane compart-
ments is controlled at multiple steps.
Key words: caveolae • membrane trafﬁc • protein 
sorting • Golgi apparatus • endoplasmic reticulum
 
Introduction
 
Caveolin-1 was originally identified as a prominent ty-
rosine phosphorylated protein in Rous sarcoma virus
transformed cells (Glenney, 1989; Glenney and Zokas,
1989). The localization of the protein to caveolae striated
coat material (Rothberg et al., 1992) initiated a program of
study to determine its function in this membrane domain.
Initially, it was thought that caveolin-1 might be a coat
protein, similar in design to clathrin or coatomer. How-
ever, cloning and sequencing of the caveolin-1 cDNA
showed that it most likely was an integral membrane pro-
tein inserted so that both ends of the molecule are in the
cytosol (Anderson, 1998) and that it did not have homol-
ogy to any coat proteins. Coimmunoprecipitation assays
indicate that caveolin-1 can interact with a variety of pe-
ripheral and integral membrane proteins (Okamoto et al.,
1998). Some of these interactions appear to involve the 33-
amino acid (aa)
 
1
 
 long hydrophobic region that is thought
to insert the protein into the lipid bilayer (Wary et al.,
1996; Das et al., 1999). Biochemical studies have shown
that a 20-aa sequence (aa 80–100) proximal to the mem-
brane insertion region interacts with a broad range of sig-
nal transducing molecules, including tyrosine kinase re-
ceptors, endothelial nitric oxide synthase (eNOS), and
heterotrimeric G proteins (for review see Okamoto et al.,
1998). This so-called scaffolding domain was used to iso-
late from a phage display library a peptide motif (
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-X-
 
f
 
-
X-X-X-
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-X-X-X-X-
 
f
 
-X-X-
 
f
 
, or 
 
f
 
-X-
 
f
 
-X-X-X-X-
 
f
 
-X-
X-
 
f
 
) that is found in several of the molecules that interact
with caveolin-1. The scaffolding domain does not appear to
be involved in targeting integral membrane proteins to ca-
veolae (Mineo et al., 1999), but may play a role in modulat-
ing signal transduction at this site (Okamoto et al., 1998).
Caveolin-1 also has an important function in intracellu-
lar cholesterol traffic. This isoform of caveolin is a choles-
terol (Murata et al., 1995) and fatty acid (Trigatti et al.,
1999) binding protein that appears to be upregulated in re-
sponse to increased levels of cellular cholesterol (Fielding
et al., 1997; Hailstones et al., 1998). Expression of caveo-
lin-1 in cultured lymphocytes that ordinarily lack the pro-
tein markedly accelerates the rate of cholesterol transport
from the ER to the plasma membrane (Smart et al., 1996).
At the same time, the caveolae membrane fraction be-
comes enriched in cholesterol and the number of invagi-
nated caveolae in the cell increases (Fra et al., 1995).
Therefore, caveolin-1 appears to play a role in maintaining
the proper level of cholesterol in caveolae.
Caveolin-1 is found in the Golgi apparatus (Luetterforst
et al., 1999) and at the cell surface (Rothberg et al., 1992)
of most normal tissue culture cells. As much as 90% of the
cellular caveolin-1 is at the cell surface (Das et al., 1999),
and immunogold labeling indicates that the majority of
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this pool is localized to caveolae (Rothberg et al., 1992).
Some of the Golgi-associated caveolin-1 is in transit from
its site of synthesis in the ER (Monier et al., 1995) to the
cell surface. Indeed, the Golgi apparatus may be a site of
caveolae assembly (Lisanti et al., 1993). Surface caveolin-1
also recycles through the Golgi apparatus using a novel
pathway that involves the direct movement of the mole-
cule from caveolae to the lumen of the ER and on to the
Golgi apparatus (CERGA) (Conrad et al., 1995; Smart et al.,
1994). A cytoplasmic pool of caveolin-1 that is in a com-
plex with multiple chaperones may be an intermediate in
the CERGA pathway (Uittenbogaard et al., 1998). Fi-
nally, caveolin-1 probably recycles in caveolae vesicles re-
turning to the cell surface after internalization during po-
tocytosis (Parton et al., 1994).
Immunofluorescence cannot distinguish between the re-
cycling and the newly synthesized pools of caveolin-1 in
the Golgi apparatus. One potential distinguishing feature
of the CERGA pathway is that the caveolin-1 in the ER
and Golgi apparatus is not intercalated into membranes,
and therefore behaves like a soluble protein (Smart et al.,
1994). It is also not degraded when cell homogenates are
treated with proteases. On the other hand, the caveolin-1
that has been incorporated into nascent caveolae in the
Golgi apparatus is in a high molecular weight complex
(Lisanti et al., 1993) that is resistant to detergent solubiliza-
tion (Scheiffele et al., 1998). The caveolin-1 in the Golgi ap-
paratus is either in route to the cell surface from its site of
synthesis in the ER, or has arrived from a recycling pathway.
The dynamic behavior of caveolin-1 must depend on
specific domains within the protein that control its intra-
cellular traffic. These domains contain sorting information
that specifies how the molecule will transit from the ER to
the cell surface as well as its recycling itinerary. In an at-
tempt to identify some of these codes, we have expressed
multiple mutant forms of caveolin-1 and analyzed the traf-
fic pattern for each in a cell that normally expresses the
protein. We now report on the identification of four re-
gions in the molecule that control different stages of cave-
olin-1 intracellular traffic.
 
Materials and Methods
 
Materials
 
Polyclonal antibody (pAb) Myc was purchased from Upstate Biotechnol-
ogy, Inc. pAb caveolin-1 and mAb caveolin-1 number 2234 were pur-
chased from Transduction Laboratories. Anti–mannosidase II antiserum
was provided by Dr. Moremen (University of Georgia, Athens, GA).
mAb grp78 was obtained from StressGen. Alexa 488 goat anti–rabbit IgG
and Alexa 568 goat anti–mouse IgG were purchased from Molecular
Probes. Isopropyl-
 
b
 
-
 
D
 
-thiogalactoside (IPTG) was purchased from Cal-
biochem and kept at 
 
2
 
20
 
8
 
C (stock solutions 200 mM in H
 
2
 
O). BSA, pro-
line, leupeptin, soybean trypsin inhibitor, pepstatin A, and benzamidine
were from Sigma Chemical Co. Lipofectamine Plus and G418 were from
GIBCO BRL.
Protease inhibitors were stock solutions (1,000
 
3
 
) of benzamidine (500 mM
in H
 
2
 
O), leupeptin (10 mM in H
 
2
 
O), trypsin inhibitor (10 mg/ml in H
 
2
 
O),
and pepstatin (1 mg/ml in methanol). Buffers A–E consisted of the follow-
ing. Buffer A: 100 mM sodium phosphate, pH 7.4, 0.15 M NaCl, 4 mM
KCl, 2 mM MgCl
 
2
 
, and 0.02% (wt/vol) sodium azide; buffer B: 25 mM
MES, pH 6.5, 150 mM NaCl, 1:1,000 dilution of each protease inhibitor;
buffer C: 25 mM MES, pH 6.5, 150 mM NaCl, 1% Triton X-100, 1:1,000
dilution of each protease inhibitor; buffer D: 20 mM Tris, pH 8.0, 150 mM
NaCl, 1% Triton X-100, 60 mM octylglucoside, 1:1,000 dilution of each
 
protease inhibitor; and buffer E: 0.25 M sucrose, 20 mM Tricine, pH 7.8,
1 mM EDTA, 1:1,000 dilution of each protease inhibitor.
 
Cell Culture
 
CHO-K2 and CHO-K2 lacRep cells were kindly provided by Dr. Michael
Roth (Department of Biochemistry, University of Texas Southwestern
Medical Center, Dallas, TX). CHO-K2 lacRep is a stable transfected
CHO-K2 line expressing the lac repressor under control of the cytomega-
lovirus (CMV) promoter. The expression of the lac repressor was verified
by immunofluorescence using a lac repressor pAb. The cells were main-
tained in DME supplemented with 10% FCS and 20 
 
m
 
g/ml proline in a hu-
midified incubator at 37
 
8
 
C and 5% CO
 
2
 
. Cells were grown in 100-mm cell
culture dishes until 
 
z
 
70–80% confluent before inducing the expression of
individual constructs by incubating the cells in the presence of 5 mM
IPTG for 16 h. Transfected cells were never maintained in culture longer
than 10–12 wk before replacing them with fresh cells.
 
Construction of Normal and Mutant Caveolin-1 cDNA
 
A series of mutations in caveolin-1 were generated by PCR from the orig-
inal cDNA clone of 
 
a
 
-caveolin-1 (see Fig. 1) using the Expand High Fidel-
ity PCR system (Roche). The PCR products were subcloned into the
EcoRI and HindIII sites of pCDNA3-lacRep-MycHis, a derivative of
pCDNA3-MycHis generated by excising the CMV promoter with BglII
and NotI and inserting the promoter region of pCMV3lacRep (Welch et
al., 1998). This region contains the CMV promoter with multiple lac re-
pressor binding sites. The resulting caveolin-1 wild-type and mutant con-
structs were confirmed by sequencing. The Polybrene method (Brewer,
1994) was used to transfect CHO-K2 lacRep cells with the indicated con-
struct. The transfected cells were selected with 0.6 mg/ml G418 (GIBCO
BRL) over a period of 14 d. After selection, individual clones were iso-
lated by limiting dilution and screened for inducible expression of wild-
type or mutant caveolin-1 by immunofluorescence and immunoblotting.
For transient expression of Cav
 
134-178
 
, CHO-K2 cells were transiently
transfected with the construct using Fugene 6 (Roche) according to the
manufacturer protocol.
 
Immunofluorescence Microscopy
 
Cells (2 
 
3
 
 10
 
5
 
/well) were seeded into individual wells of a 24-well plate
containing 12-mm glass coverslips and grown until 50% confluent before
the addition of 5 mM IPTG for 16 h. Cells were then fixed in 100% meth-
anol for 5 min at 
 
2
 
20
 
8
 
C. The coverslips were sequentially incubated at
room temperature in PBS plus 0.5% BSA for 60 min, the indicated pri-
mary antibody for 30 min, and the appropriate fluorescent-tagged pAb
IgG for 30 min. The coverslips were then mounted on glass slides with
Aquamount (Polyscience) and viewed with a Leica TCS-SP Laser scan-
ning microscope.
 
Fractionation of Triton X-100 Insoluble Membranes
 
The presence of wild-type and mutant caveolin-1 in Triton X-100 insolu-
ble light membranes was determined using sucrose gradient fractionation.
Each dish of cells was washed in ice cold buffer B and then scraped from
the dish into 1 ml of buffer C. The cells were further incubated on ice for
20 min before homogenizing the sample with a dounce homogenizer. The
homogenates were transferred to a TH641 centrifuge tube and mixed with
an equal volume of 2.5 M sucrose. The sample was then overlaid with a
10–30% linear sucrose gradient and centrifuged for 21 h at 29,000 rpm in a
Sorval THP 64.1 rotor. Fractions were collected from the top of the gradi-
ent and the total protein in each fraction precipitated with TCA. Precipi-
tates were resuspended in SDS-PAGE sample buffer, separated by gel
electrophoresis, and immunoblotted with the indicated antibody.
 
Incorporation of Caveolin-1 into High Molecular 
Weight Complex
 
Velocity sedimentation was used to determine if wild-type and mutant ca-
veolin-1 were incorporated into high molecular weight complexes (Sargia-
como et al., 1995). Cells were scraped into buffer D and incubated on ice
for 30 min. After removal of cellular debris and nuclei by centrifugation
(Eppendorf Microcentrifuge) at 22,000 
 
g
 
 for 10 min at 4
 
8
 
C, the superna-
tant material was loaded on top of a linear 5–30% sucrose gradient and
centrifuged for 16 h at 50,000 rpm (340,000 
 
g
 
) in a Beckmann SW-60 rotor. 
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12 fractions were collected from the top the gradient and the protein pre-
cipitated with TCA. Precipitates were resuspended in SDS-PAGE sample
buffer, separated by gel electrophoresis and immunoblotted with the indi-
cated antibody.
 
Protease Protection Assay
 
The topology of wild-type and mutant caveolin-1 in the membrane was de-
termined as described previously (Smart et al., 1994). Cells from a 100-mm
cell culture dish were collected in 1 ml buffer E and homogenized in a Pot-
ter Elvjhem homogenizer. The nuclei and unbroken cells were removed
by centrifuging the sample at 1,000 
 
g
 
 for 10 min at 4
 
8
 
C. The supernatant
fraction was centrifuged for 1 h at 100,000 
 
g
 
 in a Beckmann 100.3 rotor.
The pellet was resuspended in 1 ml buffer A and transferred to micro-
tubes. Each sample was then incubated for 30 min on ice either in buffer
alone, 300 
 
m
 
g/ml trypsin, or trypsin plus 1% Triton X-100. The total pro-
tein in each sample was precipitated with TCA. Precipitates were resus-
pended in SDS-PAGE sample buffer, separated by gel electrophoresis,
and immunoblotted with the indicated antibody.
 
Detection of Caveolin-1 Oligomers
 
To detect caveolin oligomers, IPTG induced cells grown on a 35-mm dish
were collected in 200 
 
m
 
l SDS sample buffer and solubilized by sonication
(three times 40 J bursts). Without boiling, the samples were separated by
SDS-PAGE on a 3–20% gradient gel and immunoblotted with the indi-
cated antibody (Monier et al., 1996).
 
Immunoblotting
 
Equal volume fractions were incubated in SDS sample buffer (Laemmli,
1970) at 95
 
8
 
C for 5 min and separated by electrophoresis at 25 mA per gel.
The proteins were transferred to polyvinylidene difluoride membranes
(Millipore Corp.). After blocking with TBST (20 mM Tris, pH 8.0, 137 mM
NaCl, 0.4% Tween 20) containing 5% nonfat dry milk, the membranes
were incubated with the first antibody in TBST containing 1% nonfat dry
milk followed by the second antibody in TBST containing 1% nonfat dry
milk. Bound antibody was detected using an ECL detection system (Am-
ersham Pharmacia Biotech).
 
Results
 
The strategy used in this study was to express various mu-
tant forms of Myc-tagged caveolin-1 (listed in Fig. 1) and
look at the distribution of the Myc epitope using immuno-
fluorescence, immunoelectron microscopy, and cell frac-
tionation. We used CHO cells stably transfected with an
expression plasmid controlled by an IPTG regulated pro-
moter. The CHO cell, which normally expresses caveolin-1,
was chosen for these studies so that we could screen for
mutant caveolin-1 that might alter the distribution of the
endogenous protein or have a dominant-negative effect on
caveolae function. More importantly, we wanted to use a
cell that was able to properly sort endogenous caveolin-1.
 
Localization of Mutant Caveolins
 
We began by expressing the full-length 
 
a
 
 isoform of cave-
olin-1 (Fig. 2) and found this Myc-tagged, ectopically ex-
pressed protein was primarily at the cell surface in associa-
tion with the endogenous protein (Cav
 
1-178
 
; Fig. 2, A and
B). Immunogold labeling of Lowicryl K4M sections con-
firmed that the Myc epitope was localized to invaginated
caveolae (data not shown). The exact same distribution
was seen for the 32-aa, shorter 
 
b
 
 isoform (Cav
 
32-178
 
; data
not shown). Removing 60 aa from the NH
 
2
 
 terminus did
not affect the distribution of the protein (Cav
 
60-178
 
; Fig. 2
C), but the loss of an additional 41 aa caused the protein to
accumulate in the interior of the cell (Cav
 
101-178
 
; Fig. 2 D).
The immunofluorescence pattern for Cav
 
101-178 
 
suggested
it was in the ER and nuclear envelope. Further truncation
of the protein by removing the putative membrane inser-
tion site caused it to accumulate in the nuclear envelope
and the Golgi region of the cell (Cav
 
134-178
 
; Fig. 2, E and F).
Cav
 
134-178 
 
only partially colocalized with the Golgi marker
mannosidase II (compare Fig. 2 E with Fig. 2 F).
Removal of the last 22 aa of caveolin-1 had no effect on
its distribution (data not shown). Cav
 
1-134
 
, by contrast,
colocalized with mannosidase II (Fig. 3, A and B). Cav
 
1-101
 
had a diffuse, cytoplasmic distribution consistent with the
behavior of a cytosolic protein (data not shown). Finally,
when we removed both the NH
 
2
 
- (aa 1–100) and the
COOH-terminal (aa 134–178) portions of the molecule,
the remaining 33 aa hydrophobic piece had an ER and nu-
clear envelope staining pattern (Cav
 
101-134
 
; Fig. 3 C).
The behavior of the various truncated caveolins indi-
cates that there are at least two domains within the mole-
cule that influence its intracellular traffic. A region be-
tween aa 60 and 101 influences the exit of the protein from
the ER, whereas the region between aa 134 and 156 is re-
quired for migration from the Golgi apparatus to the cell
surface. To gain better resolution of these two controlling
Figure 1. Schematic representation of normal and mutant caveo-
lin-1. The 17 different constructs of caveolin-1 used in this study
are depicted as bar diagrams, beginning with wild-type caveolin-1
(Cav1-178). Three landmarks in the protein are: the highly con-
served signature domain, aa 68–75 (solid box); the scaffolding do-
main, aa 80–100 (hatched box); and the membrane insertion do-
main, aa 101–133 (stippled box). The thin connecting line
indicates the position of the deleted segment. Eight of the con-
structs (Cav61A65 to Cav96A100) have the indicated aa replaced with
alanine residues. The location of the alanine substitution in each
construct is indicated by the gray box. The columns beside each
bar diagram indicates the principal site of accumulation in CHO
cells of each construct and whether or not it is soluble in Triton
X-100. 
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Figure 2. Location of NH2-
terminal deletion mutants of
caveolin-1. CHO cells either
stably transfected with Myc-
tagged forms of Cav1-178 (A
and B), Cav60-178 (C), or
Cav101-178 (D) under control
of an IPTG inducible pro-
moter or transiently trans-
fected with Cav134-178 (E and
F) were grown on coverslips.
Cells were either induced for
16 h with 5 mM IPTG (A–D)
or not treated (E and F).
CHO cells expressing Cav1-178
were costained with Myc
pAb (A) and caveolin mAb
(B). CHO cells expressing ei-
ther Cav60-178 (C) or Cav101-178
(D) were stained with Myc
pAb. CHO cells transiently
expressing Cav134-178 were
double-stained with man-
nosidase II pAb (E) and Myc
mAb (F). Bars, 10 mm. 
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elements, we constructed expression vectors coding for
proteins that had portions of these regions deleted (Fig. 4).
A caveolin-1 lacking aa 60–100 had an ER distribution
(Cav
 
D
 
60-100
 
;
 
 
 
Fig. 4 A), whereas deletion of aa 134–154 gave
a Golgi staining pattern (Cav
 
D
 
134-154
 
; Fig. 4 D). Cav
 
D
 
60-100
 
colocalized with the ER marker protein BIP (BIP; Fig. 4
B) and Cav
 
D
 
134-154
 
 with mannosidase II (mannII; Fig. 4 C).
Next we expressed a caveolin-1 with either aa 60–80
Figure 3. Location of caveolin-1 with COOH-terminal deletions (A and B) and of the membrane insertion domain alone (C). (A and
B) CHO cells stably transfected with Myc-tagged Cav1-134 were grown on coverslips and induced for 16 h with 5 mM IPTG. Cells were
processed for double immunofluorescence labeling with mannosidase II pAb (A) and Myc mAb (B). (C) CHO cells were transiently
transfected with Myc-tagged Cav101-134 and grown on coverslips for 24 h. Cells were processed for indirect immunofluorescence using
Myc pAb. Bars, 10 mm.
Figure 4. Effect of internal deletions on location of caveolin-1. CHO cells stably transfected with either Myc-tagged CavD60-100 (A and
B), CavD134-154 (C and D), CavD60-80 (E and F), or CavD80-100 (G and H) under control of an IPTG inducible promoter were grown on cov-
erslips. Cells were processed for indirect immunofluorescence localization of either the Myc epitope (A, D, E, and H), BIP (B and F), or
mannosidase II (C and G). Bars, 10 mm. 
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(Cav
 
D
 
60-80
 
; Fig. 4 E) or aa 80–100 removed (Cav
 
D
 
80-100
 
; Fig.
4 H). Interestingly, Cav
 
D
 
60-80 
 
had an ER distribution,
whereas Cav
 
D
 
80-100 
 
was only found in the Golgi appara-
tus. Double immunofluorescence confirmed that Cav
 
D
 
60-80
 
colocalized with BIP (Fig. 4 F) and Cav
 
D
 
80-100 
 
with man-
nosidase II (Fig. 4 G). Immunogold EM verified the loca-
tion of these two constructs (data not shown). Therefore,
between aa 60 and 100 there appears to be two trafficking
signals, one for transit of caveolin-1 out of the ER and one
for movement from the Golgi apparatus to the cell surface.
The sequence from aa 68 to 75 is the most conserved
segment of the molecule between 
 
C. elegans
 
 and humans
(designated the signature domain), whereas the region be-
tween aa 80 to 101 is thought to modulate the activity of
multiple signal transducing molecules (the scaffolding do-
main) (Okamoto et al., 1998). We sequentially replaced
5-aa long segments from aa 60 to 101 with alanine residues
and analyzed by immunofluorescence the distribution of
each mutant form (Fig. 5). Replacing aa 61–65 with ala-
nines had no effect on the distribution of the protein (com-
pare endogenous [Fig. 5 A] with Cav
 
61A65 
 
[Fig. 5 B]). By
contrast, substitution of the next five aa with alanines
caused the protein to accumulate in the ER (compare
Cav
 
66A70 
 
[Fig. 5 C] with BIP [Fig. 5 D]). Caveolins bearing
any of the other substitutions (Cav
 
71A75
 
, Fig. 5 E; Cav
 
76A80
 
,
Fig. 5 F; Cav
 
81A85
 
, Fig. 5 G; Cav
 
86A90
 
, Fig. 5 H; Cav
 
91A95
 
,
Fig. 5 I; and Cav
 
96A100
 
, Fig. 5 J) primarily had a perinuclear
 
distribution similar in character to a Golgi pattern of
staining.
 
Organization of Mutant Caveolins in the Cell
 
The results so far indicate there are three regions in the ca-
veolin-1 molecule that exert control over its intracellular
location. The 20-aa long regions on either side of the puta-
tive membrane anchor modulates departure from the
Golgi apparatus. The five aa between positions 66 and 70
control exit from the ER. To better understand why these
mutant forms are not properly localized in the cell, we
used a series of biochemical tests that measure the topol-
ogy and turnover of these proteins as well as their ability
to interact with themselves and with other cellular pro-
teins.
When caveolin-1 is in caveolae it behaves like an inte-
gral membrane protein oriented with both ends in the cy-
toplasm (Kurzchalia and Parton, 1996). As a consequence,
most of the caveolin-1 in the cell is protease-sensitive, ex-
cept when it collects in the ER lumen of cells exposed to
cholesterol oxidase (Smart et al., 1994). We used protease
sensitivity to determine the topology of various mutant ca-
veolins (Fig. 6). Cells expressing either wild-type or the
indicated mutant caveolin-1, all tagged with the Myc
epitope, were homogenized and high-speed membrane
pellets were prepared. The pellet was incubated in the
Figure 5. Effect of alanine-substitution on location of caveolin-1. CHO cells stably transfected with either Myc-tagged Cav61A65 (A and
B), Cav66A70 (C and D), Cav71A75 (E), Cav76A80 (F), Cav81A85 (G), Cav86A90 (H), Cav91A95 (I), or Cav96A100 (J) under control of an IPTG in-
ducible promoter were grown on coverslips in the presence of IPTG for 16 h. Cells were processed for indirect immunofluorescence lo-
calization of the Myc epitope (A, C, and E–J), caveolin-1 (B), or BIP (D). Bars, 10 mm.Machleidt et al. Caveolae, Caveolin-1, Membrane Traffic, Protein Sorting 23
presence (Fig. 6, lanes 2, 3, 5, 6, 8, 9, 11, 12, 14, 15, 17, 18,
20, and 21) or absence (Fig. 6, lanes 1, 4, 7, 10, 13, 16, and
19) of trypsin or with trypsin plus Triton X-100 (Fig. 6,
lanes 3, 6, 9, 12, 15, 18, and 21). The membranes were sep-
arated by gel electrophoresis at the end of the incubation
and immunoblotted with either pAb Myc or a pAb against
the luminal ER protein, BIP (Hebert et al., 1995). Regard-
less of the mutant form, all of these tagged caveolins were
protease-sensitive without the addition of detergents. Most
of the BIP, on the other hand, was resistant to protease
treatment, indicating that it was protected within the ER
lumen. BIP was destroyed by the protease when the mem-
brane was permeabilized with Triton X-100. Similar re-
sults were obtained when pAb caveolin-1 was substituted
for pAb Myc (data not shown). Therefore, regardless of
whether the mutant caveolin-1 was in the ER (CavD60-80,
Cav66A70), the Golgi apparatus (CavD80-100, Cav91A95,
Cav81A85), or caveolae (Cav61A65), it appeared to retain the
same orientation as the wild-type protein. This indicates
that mutant forms of caveolin-1 would not be able to inter-
act with chaperones in the lumen of either the ER or Golgi
apparatus.
Despite having the correct orientation in the membrane,
the mislocalized mutant forms of caveolin-1 could be
trapped in these locations as a consequence of being par-
tially unfolded. One measure of misfolding is a rapid rate
of turnover relative to the wild-type protein. This is be-
cause cells have a quality control mechanism that recog-
nizes misfolded ER and cytoplasmic proteins and rapidly
shunts them to the ubiquitin/proteasome pathway for deg-
radation (Kopito, 1997). Caveolin-1 has a relatively slow
turnover time, so we used immunoblotting to compare the
rate of disappearance of Myc-tagged wild-type and mutant
caveolin-1 from cells that had been incubated in the pres-
ence of cycloheximide (Fig. 7). During an 8-h incuba-
tion in the presence of this drug, there was very little loss
of wild-type Cav1-178 from the cell. CavD60-80, CavD60-100,
Cav66A70, and Cav61A65 were also quite stable. By contrast,
the degradation of CavD80-100, Cav81A85, Cav96A100, and
Cav101-178 was markedly accelerated. The turnover of both
CavD134-154 and Cav71A75 was only slightly faster than the
wild-type protein. Therefore, there appears to be no corre-
lation between where individual mutant caveolins accu-
mulate in the cell and their rate of turnover. To the extent
that rapid degradation measures misfolding, the Cav66A70
Figure 6. All mutant forms
have a wild-type orientation.
CHO cells expressing the in-
dicated Myc-tagged caveo-
lin-1 construct were ho-
mogenized as described in
Materials and Methods. Ali-
quots of the homogenate
were either not treated
(lanes 1, 4, 7, 10, 13, 16, and
19), incubated in the pres-
ence of 300 mg/ml trypsin for
30 min on ice (lanes 2, 5, 8,
11, 14, 17, and 20), or incu-
bated in the presence of 1%
Triton X-100 plus trypsin
(lanes 3, 6, 9, 12, 15, 18, and
21). Samples were separated
by SDS-PAGE and immuno-
blotted with Myc pAb.
Figure 7. Turnover of wild-type and mutant caveolin-1. CHO
cells stably expressing the indicated Myc-tagged caveolin-1 con-
struct were either not treated (lane 1) or incubated in the pres-
ence of 500 mM cycloheximide for 1 (lane 2), 2 (lane 3), 4 (lane
4), 6 (lane 5), or 8 h (lane 6). At the end of the incubation, the
cells were lysed, separated by SDS-PAGE, and immunoblotted
with Myc pAb. The table indicates the predominant location of
the construct as determined by immunofluorescence.The Journal of Cell Biology, Volume 148, 2000 24
in the ER and the CavD134-154 in the Golgi apparatus seem
to have relatively normal conformations.
Several studies indicate that the caveolin-1 in caveolae
forms a high molecular weight complex with itself and
with caveolin-2 (Das et al., 1999). Other proteins may be
in the complex as well. We used velocity sedimentation to
determine if any of the mutant forms of caveolin-1 were
impaired in complex formation (Fig. 8). Cells expressing
each construct were solubilized in octylglucoside and cen-
trifuged at low speed to remove nuclei and cellular debris.
The supernatant fraction was loaded on the top of a 5–30%
sucrose gradient containing 60 mM octylglucoside and cen-
trifuged at 340,000 g for 16 h. 12 fractions were collected
from the top of the gradient, separated by gel electro-
phoresis, and immunoblotted. The wild-type and the mu-
tant caveolins that traffic normally to the cell surface were
all found in complexes that sediment to the bottom of the
gradient (Cavendo, Cav1-178, Cav60-178, and Cav61A65). The
ER-located CavD60-100 was not in a complex nor were the
Golgi-located CavD60-100, Cav91A95, Cav96A100, and Cav1-134.
The ER-associated Cav66A70 and the Golgi-associated
Cav81A85 and Cav86A90 only partially localized to com-
plexes. Surprisingly, the Cav71A75 and Cav76A80, which both
accumulate in the Golgi apparatus, were exclusively in the
high molecular weight region of the gradient. Therefore,
the ability of caveolin-1 to assemble into high molecular
weight complexes may be necessary to reach the cell sur-
face, but it is not sufficient.
High molecular weight complexes of caveolin-1 are of-
ten seen migrating at the top of SDS polyacrylamide gels
after electrophoresis. We used SDS-PAGE to determine
how the mutant caveolins migrated (Fig. 9). Samples of
membranes from cells induced to express wild-type and
mutant caveolin-1 were separated by SDS gel electro-
phoresis and immunoblotted with pAb Myc. Oligomeric
a- (Fig. 9, lane 1) and b-caveolin-1 (Fig. 9, lane 2) ap-
peared as prominent bands on the gel. As observed previ-
ously (Monier et al., 1995), more of the b isoform was oli-
gomerized than the a isoform relative to the amount of
monomer on the gel. CavD60-80 (Fig. 9, lane 5) and CavD80-100
(Fig. 9, lane 4) did not form any oligomer, nor did CavD134-154
(Fig. 9, lane 3). Whereas the introduction of alanine resi-
dues between aa 65 to 71 (Fig. 9, lane 7) and 90 to 101 (Fig.
9, lane 10) completely abolished oligomerization, oligomer
formation was normal for Cav61A65 (Fig. 9, lane 6) and
Cav71A75 (Fig. 9, lane 8). The amount of oligomer formed
by the Cav81A85 (Fig. 9, lane 9) mutant was intermediate
between wild-type and CavD80-100. Therefore, both the sed-
imentation and the SDS-PAGE assay agree that specific
mutations impair the ability of caveolin-1 to form high mo-
lecular weight complexes.
Caveolin-1 oligomer formation is associated with the in-
corporation of the molecule into detergent resistant, light
membranes (Scheiffele et al., 1998). These membranes
tend to form in the Golgi apparatus (Brown and Rose,
1992; Lisanti et al., 1993). We used a standard assay to
measure the ability of wild-type and mutant forms of cave-
olin-1 to float on sucrose gradients after Triton X-100
treatment of whole cells. Cells expressing the indicated
constructs were homogenized in Triton X-100, layered on
the bottom of a sucrose gradient, and centrifuged at
29,000  g for 21 h. (Fig. 10). Equal volume fractions were
separated by gel electrophoresis and immunoblotted with
either pAb Myc or pAb caveolin-1. Endogenous caveolin-1
(Cavendo) quantitatively floated in fractions 5–9, indicating
that nearly all of the protein was incorporated into Triton
X-100 insoluble light membranes. All of the Myc-tagged,
wild-type caveolin-1 was in this fraction too. However,
Figure 8. Ability of wild-type and mutant caveolin-1 to form high
molecular complexes. CHO cells or CHO cells stably expressing
the indicated Myc-tagged caveolin-1 construct were extracted
with buffer containing 60 mM octylglucoside. The lysate was
loaded on the top of a 5–30% continuous sucrose gradient and
centrifuged for 16 h at 340,000 g. Fractions were collected from
the top of the gradient, separated by gel electrophoresis, and im-
munoblotted with either a caveolin-1 pAb (Cavendo) or Myc pAb
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with the exception of Cav61A65, none of the mutant caveo-
lins floated in these fractions. Even Cav71A75 and Cav76A80,
which are able to oligomerize, were not incorporated into
Triton X-100 insoluble light membranes.
Discussion
In previous studies, mutagenesis has been used to identify
functional elements of caveolin. The key discoveries that
have come from this approach include: the isolation of a
dominant-negative acting form of caveolin-3 (Roy et al.,
1999); the identification of a region in caveolin-1 that in-
teracts with multiple signaling molecules (Okamoto et al.,
1998); the identification of regions in caveolin-1 that affect
vesicle formation in Sf21 cells (Li et al., 1996) and control
homo-oligomerization (Song et al., 1997; Li et al., 1998);
and the identification of a putative Golgi apparatus target-
ing sequence in caveolin-3 (Luetterforst et al., 1999).
These investigations have employed a variety of in vitro
and in vivo techniques as well as used diverse cellular sys-
tems to express the normal and mutant forms. As a conse-
quence, it is sometimes difficult to relate the results of
each study to the normal behavior of caveolin-1 in the cell.
The goal of this study was to understand the molecular ba-
sis of caveolin-1 sorting as the molecule moves through
various membrane compartments. The success of this
analysis depended on using a cell that was actively pro-
cessing and properly sorting the protein. Therefore, we
introduced normal and mutant Myc-tagged forms of
caveolin-1 into cells expressing the endogenous protein.
Although it is possible that interactions between the
expressed protein and endogenous caveolin-1 masked
crucial sorting information, we were still able to identify
four regions of the molecule that are involved in sorting
caveolin-1 during its transit through ER and Golgi mem-
branes. Three of these regions are involved in sorting
events that occur in the Golgi apparatus, whereas the
fourth operates during sorting from the ER.
Accumulation in the ER
Replacing the 5-aa long segment 66IDFED70 with ala-
nine residues causes caveolin-1 to accumulate in the ER.
Figure 9. Ability of wild-type and mutant caveolin-1 to form oli-
gomers. Samples of CHO cells expressing the indicated Myc-
tagged caveolin construct were collected in sample buffer con-
taining 2% (wt/vol) SDS and 5% (vol/vol) 2-b-mercaptoethanol
and solubilized by sonication. Samples were separated on 3–20%
polyacrylamide gradient gels and immunoblotted with Myc pAb.
Figure 10. Ability of wild-type and mutant caveolin-1 to incorpo-
rate into Triton X-100 insoluble, light membranes. CHO cells or
CHO cells stably expressing the indicated Myc-tagged caveolin-1
construct were extracted with 1% Triton X-100 at 48C overlaid
with a 10–30% sucrose gradient. The detergent insoluble fraction
was separated from the soluble fraction by centrifugation at
29,000 rpm for 21 h. The gradient was fractionated from the top
(fraction 1). Equal volumes of each fraction were separated by
SDS-PAGE and immunoblotted with either caveolin-1 pAb
(Cavendo) or Myc pAb (Cav1-178 to Cav96A100) as described.The Journal of Cell Biology, Volume 148, 2000 26
A homologous sequence is present in both caveolin-2
(51LGFED55) and caveolin-3 (39VDFED43) and they all are
at similar positions in the molecule. Based on the results of
several tests, caveolin-1 with this mutation is correctly ori-
ented in the membrane, is not rapidly shunted into a
degradation pathway, and is poorly oligomerized. These
properties suggest the mutant caveolin-1 originates by
cotranslational insertion into the membrane (Monier et al.,
1995), but does not relocate to the Golgi apparatus. Either
it moves to the Golgi apparatus but is rapidly returned or
it is unable to exit from the ER.
We can think of two mechanisms to account for this be-
havior. Either an interaction between the IDFED se-
quence and an unidentified factor(s) is required to relo-
cate caveolin-1 to the Golgi apparatus, or the replacement
of this sequence with alanine residues causes retention in
the ER due to improper folding. We favor the first mecha-
nism. The 33-aa hydrophobic domain (Cav101-134) tagged
with the Myc epitope accumulated in the ER exactly like
Cav66A70. This construct does not have any cytoplasmic re-
gions, so retention in the ER due to an interaction with
chaperones is unlikely. The simple addition of the NH2-
terminal 100 aa of caveolin-1 to this peptide (Cav1-134) al-
lowed the hydrophobic region to move, along with the
NH2-terminal tail, to the Golgi apparatus. The results of
the mutagenesis and truncation experiments indicate that
there are no other regions between aa 1 and 101 that influ-
ence movement from the ER. Therefore, the IDFED se-
quence appears to be sufficient to move the caveolin-1
membrane insertion domain out of the ER. It is likely to
regulate the relocation of the full-length protein too.
Accumulation in the Golgi Apparatus
The region between aa 71 and 101 contains information
that influences the passage of caveolin-1 through the Golgi
apparatus. This sequence contains the putative scaffolding
domain (aa 81–101) and a portion of the highly conserved
region we call the signature domain (aa 68–75). Even
though mutations in both regions caused caveolin-1 to ac-
cumulate in the Golgi apparatus, we detected distinct dif-
ferences in the behavior of the two sets of mutant mole-
cules.
Caveolin-1 begins to oligomerize shortly after being syn-
thesized in the ER (Scheiffele et al., 1998). The size of the
caveolin-1 oligomer increases and becomes more Triton
X-100 insoluble as the complex moves to the cell surface
(Scheiffele et al., 1998). Triton X-100 insolubility appears
to begin in the Golgi apparatus along with the association
of caveolin-1 complexes with glycosylphosphatidylinositol
(GPI) anchored proteins (Lisanti et al., 1993). Previous
work has identified the region between aa 60 and 101 as
being involved in an oligomerization step (Sargiacomo et
al., 1995). We found that substitution of alanine residues
for any of the aa between 70 and 80 had no effect on oligo-
merization. However, the oligomers that formed were sol-
uble in Triton X-100. We also found by immunogold label-
ing that caveolin-1 bearing alanine substitutions in this
region were distributed throughout the Golgi apparatus
(data not shown). These results raise the possibility that in
the Golgi apparatus, oligomerization precedes entry into
cholesterol/glycosphingolipid-rich membranes. If this is
the case, then a function for the signature domain might
be to control access to cholesterol/glycosphingolipid-rich
membranes. This may be a critical step during the traffic of
all caveolins, because the 68FEDVIAEP75 sequence is the
longest conserved stretch of aa among the three isoforms.
Substituting sets of five alanine residues anywhere along
the 20-aa stretch between position 80 and 100 interferes
with caveolin-1 oligomerization. We saw the most com-
plete effect when the residues between 90 and 101 were re-
placed with alanine. 6 of the 10 residues in this region are
hydrophobic and 5 of these are aromatic. aa 89 is also aro-
matic. Therefore, the hydrophobicity of this region may be
a critical factor in controlling caveolin-1 oligomerization.
We also found that caveolins with alanine substitutions in
91TFTVTKYWFY100 were Triton X-100 soluble. This is
consistent with recent studies showing that caveolin 1–101
interacts with Triton X-100 insoluble, light membrane
fractions, but caveolin 1–81 does not (Schlegel et al., 1999).
Caveolin-1 with alanine substitutions in 71VIAEPEG-
THS80 was also Triton X-100 soluble and contains a nor-
mal 91TFTVTKYWFY100. This is further evidence that the
71VIAEPEGTHS80 region controls access to Triton X-100
insoluble membrane domains. Otherwise, caveolin-1 with
alanine substitutions in this region should be Triton
X-100 insoluble. However, the question remains whether
caveolin-1 with mutations in the 91TFTVTKYWFY100 se-
quence ever reaches cholesterol/glycosphingolipid-rich
membranes in the Golgi apparatus. These mutant caveo-
lins accumulate in the Golgi apparatus either because they
cannot reach these domains or are unable to remain
bound during vesicle formation.
The fourth region of caveolin-1 that controls sorting is
the sequence between aa 134 and 154. Caveolin-1 lacking
the entire COOH-terminal region (Cav1-134) accumulated
in the Golgi apparatus but was completely soluble in
Triton X-100 and unable to incorporate into high molecu-
lar weight complexes. 12 of the 20 aa between 134 and 154
are hydrophobic, and a cysteine residue at position 143
most likely is palmitoylated (Dietzen et al., 1995). When
we deleted this region, the mutant caveolin-1 also accumu-
lated in the Golgi apparatus. Removal of aa 157–178 had
no effect on sorting. CavD134-154 was unable to oligomerize
but did partially associate with Triton X-100 insoluble,
light membranes. Apparently, caveolin-1 oligomerization
depends on both aa 90–99 and 134–154. Interestingly, Song
et al. (1997) found that Cav1-140 was able to oligomerize
normally. This result suggests the sequence 135KSFLIE140
may be the region that influences oligomerization between
aa 134 and 154. Therefore, two sequences, one on each
side of the 33 membrane insertion domain, appear to act
cooperatively during caveolin-1 oligomerization.
Other Insights
There is now growing evidence that the intracellular travel
itinerary for caveolin-1 varies according to the cell type.
For example, caveolin-1 expressed in fibroblasts and some
epithelial cells is found principally in caveolae and the
Golgi apparatus (Kurzchalia et al., 1992; Rothberg et al.,
1992), whereas in pancreatic acinar cells it is targeted to
the secretory pathway (Liu et al., 1999). The focus of the
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veolins in fibroblasts that express and sort caveolin-1 to
caveolae. Three observations we made using this cell back-
ground do not agree with published reports on the behav-
ior of mutant caveolin-3 expressed in fibroblasts. First, we
found that Cav60-178 was delivered rather efficiently to the
cell surface. The equivalent sequence of caveolin-3 (Cav54-151)
expressed in CV1 cells accumulates in the Golgi apparatus
(Luetterforst et al., 1999) and in vesicular structures that
have the characteristics of lipid droplets (Roy et al., 1999).
Second, we found that caveolin-1 lacking the COOH-ter-
minal cytoplasmic region between aa 134–178 accumu-
lated in the Golgi apparatus, whereas an equivalent con-
struct of caveolin-3 (aa 1–107) seems to be retained in the
ER of CV1 cells (Luetterforst et al., 1999). Finally, we
found no evidence that the COOH-terminal cytoplasmic
portion of caveolin-1 contains a domain for targeting the
molecule to the Golgi apparatus (Luetterforst et al., 1999).
To the contrary, deletion of aa 134–154 caused caveolin-1
to accumulate in the Golgi apparatus, indicating that with-
out this region the molecule is impaired in reaching the
surface. In contrast, caveolin-1 lacking aa 154–178 be-
haved like the wild-type molecule. Most likely, CavD134-154
accumulates in the Golgi apparatus because oligomeriza-
tion is necessary for rapid movement to the cell surface
and oligomer formation is dependent on this stretch of hy-
drophobic aa.
The behavior of the various mutant forms of caveolin-1
we analyzed suggests the wild-type molecule is synthesized
as a membrane protein in the ER and then moves sequen-
tially through various compartments on its way to the cell
surface. The four different mutant forms that acted aber-
rantly were unable to move through one of these compart-
ments at a normal pace. In most instances, the mislocaliza-
tion cannot be explained by an inappropriate interaction
with endogenous caveolin-1, because the traffic of the en-
dogenous protein was relatively normal. The proper traffic
of caveolin-1, therefore, relies on intramolecular cues that
are necessary for the molecule to travel through specific
membrane compartments.
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